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Background: In non-heart-beating donor lung transplantation, postmortem 
warm ischemia poses a special challenge. Inhaled nitric oxide and pentoxi- 
fyiline have been shown to attenuate ischemia-reperfusion injury after lung 
transplantation. We hypothesized that concomitant administration of 
inhaled nitric oxide and pentoxifylline would result in a synergistic effect on 
ischemia-reperfusion lung injury. Methods: Lungs were harvested from 
non-heart-beating donors after 30 minutes of in situ warm ischemia, 
flushed, and stored for 2 hours at 4 ° C before left lung transplantation i
rats. Inhaled nitric oxide (30 ppm) was added during cadaver ventilation 
and reperfusion; pentoxifylline was given intravenously throughout reper- 
frsion. The following groups were studied (n = 8 each): control, pentoxi- 
fylline, nitric oxide, and nitric oxide + pentoxifylline. Hemodynamic ndices 
and arterial blood gases were obtained after ligation of the right pulmonary 
artery. Lung myeloperoxidase and wet/dry ratio were measured after death. 
Results: All rats that did not receive nitric oxide died within 10 minutes after 
ligation. Inhaled nitric oxide significantly decreased pulmonary vascular 
resistance and improved recipient survival. Nitric oxide + pentoxifylline 
improved pulmonary vascular resistance, arterial oxygen tension, and 
survival even further and reduced lung myeloperoxidase as compared with 
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the group that received nitric oxide only. Preservation solution flush time was 
significantly decreased in both groups receiving nitric oxide, suggesting that 
inhaled nitric oxide used during cadaver ventilation allows for a more even 
distribution of the preservation solution. Conclusion: We conclude that treat- 
ment with inhaled nitric oxide + pentoxifylline results in a synergistic 
protection from ischemia-reperfusion injury after non-heart-beating donor 
lung transplantation. This is likely the result of a dual action on the graft 
vasculature and neutrophil sequestration. (J Thorac Cardiovasc Surg 1997; 
113:821-9) 
A lthough lung transplantation is an established treatment for end-stage lung disease, the shortage 
of donors is the most widely accepted problem facing 
widespread application. Use of organs harvested from 
non-heart-beating donors is one of the possibilities 
that are currently being explored. 1 Experimental lung 
transplantation from non-heart-beating donors was 
pioneered by Egan, a Roberts, 2 Ulicny, 3 and their co- 
workers. The period of warm ischemia ssociated with 
non-heart-beating donor transplantation poses a spe- 
cial challenge, and gradual anoxic cell death and 
endothelial dysfunction have been documented to 
occur.4, 5 Warm ischemia is generally seen as more 
harmful than cold ischemia. 5 Severe ischemia-reperfu- 
sion injury occurs in about 10% to 20% of recipients of 
lungs from heart-beating donors 6and is characterized 
by acute lung injury and pulmonary hypertension, in
association with endothelial dysfunction, polymorpho- 
nuclear neutrophil (PMN) activation and sequestra- 
tion, and release of PMN- and non-PMN-derived 
reactive oxygen species] The central role of PMNs in 
mediating ischemia-reperfusion injury is well docu- 
mented, and blockade of PMN adhesion or leukocyte 
depletion results in improved lung function after trans- 
plantation. 8 
Nitric oxide (NO), the endothelium-dependent 
relaxing factor, is associated with endothelial ho- 
meostasis. 9 It is a potent vasodilator and inhibits 
PMN adhesion to the endothelium. 7 During early 
reperfusion, pulmonary endogenous NO levels 
plummet, 9 and a recent study has shown that in- 
haled NO attenuates ischemia-reperfusion injury 
after porcine lung transplantation. 1° 
Pentoxifylline (PTX), a methylxanthine deriva- 
tive, has been shown to reduce PMN-dependent 
lung injury in several animal models. 11-14 Previous 
studies from our laboratory, as well as others, dem- 
onstrated that PTX reduces ischemia-reperfusion 
injury after experimental lung transplantation a d in 
an isolated rat lung model. 11-13 
Therefore we hypothesized that inhaled NO, 
given during cadaver ventilation and reperfusion, 
and PTX, given during reperfusion, might have a 
beneficial synergistic effect on ischemia-reperfu- 
sion injury and might improve survival after lung 
transplantation from non-heart-beating donors. 
Material and methods 
Thirty-two normal weight-matched pairs of male Sprague- 
Dawley rats (Iffa Credo, Paris, France) weighing 300 to 350 
gm were used. All animals received humane care in compli- 
ance with the "Principles of Laboratory Animal Care" 
formulated by National Society for Medical Research and 
the "Guide for the Care and Use of Laboratory Animals" 
prepared by the Institute of Laboratory Animal Resources 
and published by the National Institutes of Health (NIH 
publication No. 86-23, revised 1985). 
Non-heart-beating donor preparation. The donor rats 
were anesthetized with sodium thiopental (50 mg/kg 
intraperitoneally). After median laparosternotomy, 
each animal was exsanguinated through the abdominal 
aorta and put to death with hypovolemia. Heparin was 
not given. Donor death was identified by cessation of 
cardiac activity. Immediately after being put to death, 
the animal was tracheostomized and its lungs were 
ventilated with a Harvard rodent ventilator (model 680, 
Harvard Apparatus Co., Inc., S. Natick, Mass.) at a rate 
of 60 breaths/rain, a tidal volume of 10 ml/kg, and a 
positive end-expiratory pressure of 1 cm H20. Ventila- 
tion was performed with a gas mixture (60% oxygen, 
40% nitrogen) supplemented or not with NO at 30 ppm. 
Non-heart-beating donor animals were maintained in 
the supine position and left at room temperature for 30 
minutes. 
Lung harvest. A polyethylene cannula was inserted into 
the pulmonary artery through the right ventricle and 
ligated. After the incision of the left atrium, both lungs 
were flushed with 25 ml of an extracellular type of 
preservation solution (Celsior solution, Pasteur-M6rieux, 
Lyon, France), cooled to 4 ° C, through the pulmonary 
arterial cannula t a pressure of 20 cm H20. The compo- 
sition of Celsior solution was as follows: lactobionate, 80 
mmol/L; mannitol, 60 retool/L; reduced glutathione, 3
retool/L; glutamate, 20 retool/L; histidine, 30 retool/L; 
potassium, 15 retool/L; sodium, 100 retool/L; chloride, 
41.5 retool/L; magnesium, 13 retool/L; and calcium, 0.26 
mmol/L. Reduced glutathione was stocked in a separate 
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air-proof syringe and added to the preservation solution 
immediately before use. The time required to perfuse the 
25 ml of preservation solution at constant pressure (20 cm 
H20) was recorded as an index of pulmonary vascular 
resistance during harvest after postmortem warm isch- 
emia and was considered the pulmonary artery flush time. 
The pulmonary artery and pulmonary vein were divided as 
proximally as possible, the bronchus was ligated with the 
lung partially inflated and then divided, and the lung was 
removed. The cuffs made from 16-gauge intravenous 
Teflon catheters (Critikon, Inc., Tampa, Fla.) were placed 
in the lumina of the pulmonary artery and pulmonary vein 
and fixed with 7-0 Prolene suture (Ethicon, Inc., Somer- 
ville, N.J.). The lung was then stored at 4 ° C for 2 hours in 
a container filled with saline solution. The average time 
required to harvest he lung was 15 minutes. 
Orthotopic right lung transplantation. The recipient 
rats were premedicated by intramuscular injection of 
atropine (1.25 mg/kg) and anesthetized with intraperito- 
neal administration of sodium thiopental (50 mg/kg). 
After tracheostomy, the animals' lungs were ventilated at 
a rate of 60 breaths/min, a tidal volume of 10 ml/kg, and a 
positive end-expiratory pressure of 1 cm H20. Ventilation 
was performed with a gas mixture (60% oxygen, 40% 
nitrogen). A left thoracotomy was performed at the fourth 
intercostal space. The left bronchus, pulmonary artery, 
and pulmonary vein were isolated, crossclamped, and 
divided as distally as possible, and the native lung was 
removed. The bronchus cuff was placed immediately 
before transplantation to allow the donor lung to be 
inflated as soon as possible. The cuffs were connected to 
their respective structures in the recipient and anchored 
with 6-0 Prolene sutureJ 5 The bronchial crossclamp was 
released first to allow ventilation. The vascular clamps 
were then released to reestablish blood flow, and the rat 
lung grafts were reperfused up to 1 hour (or until recipient 
death). Warm ischemic time during connection of the 
cuffs was maintained below 12 minutes. 
Measurement of lung graft function. Lung graft func- 
tion was measured as described by Naka and associatesJ 6 
After lung transplantation, the recipient was placed in the 
supine position and a transverse thoracosternotomy was 
performed in the fourth intercostal space. Polyethylene 
cannulas (external diameter i mm) were introduced into the 
main pulmonary artery and left atrium. A perivascular flow 
probe (type 4 RB, Transonic Systems Inc., Ithaca, N.Y.) was 
then placed around the main pulmonary artery. Pulmonary 
arterial pressure (PAP) and left atrial pressure (LAP), in 
millimeters of mercury, were continuously monitored with a 
P23 ID transducer (Statham, France), and pulmonary artery 
flow (PA flow) was measured with a model T106 small 
animal blood flowmeter (Transonic Systems Inc.). Pulmo- 
nary vascular esistance (PVR) was calculated as follows: 
PVR = (mean PAP - LAP)/PA flow (millimeters of 
mercury per milliliter per minute). Arterial blood gas anal- 
yses were done with an ABL-2 gas analyzer (Radiometer 
A/S, Copenhagen, Dgnmark). Baseline measurements of
hemodynamics and arterial gas analysis were taken 30 min- 
utes after reperfusion. The native right pulmonary artery was 
then ligated, and serial measurements of hemodynamics 
were taken every 5 minutes until the animal was killed at 60 
minutes after onset of reperfusion (or until recipient death). 
Thirty minutes after ligation of the native right pulmonary 
artery or immediately before cessation of cardiac mechanical 
activity, arterial gas analysis was done. Thirty minutes after 
ligation of the right pulmonary artery, or at the time of 
recipient death, the transplanted lungs were removed, rinsed 
briskly in physiologic saline solution, and divided into two 
parts. One part was snap frozen in liquid nitrogen until the 
time of myeloperoxidase assay (MPO), performed by means 
of the method escribed by Mullane, Kraemer, and Smith. 17 
The other was dried in an oven at 60 ° C and weighed daily 
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Fig. 2. Effect of nitric oxide (NO) on preservation solu- 
tion flush time (time required to perfuse 25 ml at constant 
pressure). Data are shown as the mean + standard error 
of the mean. *p < 0.05 versus control; ?p < 0.05 versus 
pentoxifylline group (PTX). 
until the dry weight was stable for more than 5 days, to allow 
determination f the wet/dry lung weight ratio. 
Gas preparation. NO gas was purchased from CFPO 
Inc. (Paris, France) as a mixture of 450 ppm in pure nitrogen. 
Inspired gas was mixed at the concentration f 60% oxygen 
and 40% nitrogen, supplemented or not with NO (30 ppm), 
and stored in a balloon. The concentrations of NO and 
nitrogen dioxide were assessed by means of the electrochem- 
ical method (NOxBox, Bedfont Scientific Ltd., United King- 
dom). The gas mixture was passed through the soda-lime 
bottle just before it entered the ventilator. 
PTX administration. PTX (Hoechst, Paris, France) 
diluted in saline solution was given as an intravenous 
bolus of 1 mg/kg, which was followed by a continuous 
infusion as a dosage of 1.5 mg/kg per hour. PTX admin- 
istration was started 15 minutes before reperfusion and 
continued throughout the reperfusion period. 13 
Graft tissue MPO activity. MPO, a marker enzyme 
specific to PMNs, can be used as an indirect measure of 
tissue PMN infiltration. The method described by Mul- 
lane, Kraemer, and Smith 17 was used. In brief, lung tissue 
was homogenized in 10% weight/volume of hexadecyltri- 
methyl ammonium bromide phosphate buffer with a Poly- 
tron homogenizer (Kinematica, Luzern, Switzerland). The 
homogenate was sonicated, frozen at -70 ° C, thawed, and 
centrifuged. Supernatant was assayed for MPO activity 
spectrophotometrically. The change in absorbance was 
measured on a spectrometer (model 25, Beckman, Fuller- 
ton, Calif.). One unit of MPO activity is defined as the 
activity degrading 1/xmol of peroxide per minute at 25 ° C. 
Experimental protocol (Fig. 1). The following four 
groups were studied (n = 8 each): control, PTX, NO, and 
NO+PTX. In the control and PTX groups, the lungs of 
non-heart-beating donors and recipients were ventilated 
without NO. In the NO and NO+PTX groups, the lungs 
of non-heart-beating donors and recipients were venti- 
lated with the addition of inhaled NO. 
Statistical analysis. Results are expressed as mean -+ 
standard error of the mean. Statistical analysis was per- 
formed by nonpaired Student's t test, two-way analysis of 
variance, and Fisher's test for multiple comparison using 
SUPERANOVA (Abacus Concepts, Berkeley, Calif.). 
Comparisons of survival after ligation of the native right 
pulmonary artery were made by Kaplan-Meier and log- 
rank analysis. Ap value < 0.05 was considered significant. 
Results 
Pulmonary arterial flush time (Fig. 2). Pulmo- 
nary arterial flush times of the groups treated with 
inhaled NO were significantly shorter (p = 0.0001) 
than those of the groups treated without NO. 
Recipient survival (Fig. 3). All rats that did not 
receive NO died within 10 minutes after ligation of the 
right pulmonary artery (within 40 minutes of reperfu- 
sion). Survival was significantly improved in groups 
that received NO alone (p = 0.02) or NO+PTX (p = 
0.01). Survival in the group that received NO+PTX 
was further enhanced (p = 0.02). 
Hemodynamic measurements (Figs. 4 and 5). 
Five minutes after ligation of the right pulmonary 
artery, pulmonary arterial flow and pulmonary vas- 
cular resistance were significantly increased and 
decreased (p = 0.001 and p = 0.0001, respectively) 
by inhaled NO, given either alone or with the 
addition of PTX, as compared with the control and 
the PTX groups. Thus PTX alone had no effect on 
pulmonary arterial flow or pulmonary vascular e- 
sistance. However, pulmonary arterial flow was sig- 
nificantly increased (p = 0.04) by inhaled NO +PTX, 
as compared with inhaled NO alone, indicating that 
PTX had an additive effect on the action of NO. 
Because all recipients of groups that did not receive 
NO died within 10 minutes of the right pulmonary 
artery ligation, pulmonary arterial flow and pulmo- 
nary vascular esistance were compared again, be- 
tween the group that received NO alone and the 
group that received NO+PTX,  at a late phase, that 
is, at the final time at which recipients were alive. 
Again, similar to the results obtained at 5 minutes, 
treatment with inhaled NO + PTX resulted in signif- 
icantly improved pulmonary arterial flow (p = 0.01) 
as compared with inhaled NO alone. 
Gas exchange. Arterial blood gases were mea- 
sured at the latest possible time, either at 30 minutes 
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control group; tp < 0.05 versus pentoxifylline group (PTX); ~ < 0.05 versus nitric oxide group (NO). 
after pulmonary artery ligation for the survivors or 
immediately before cessation of cardiac activity for 
the others,. Rats treated with inhaled NO+PTX had 
the best oxygenation (175 _+ 28 mm Hg, p = 0.0006) 
as compared with all other groups (79.5 _+ 21 mm 
Hg in the NO group, 53 _+ 2 mm Hg in the PTX 
group, and 49 +_ 10 mm Hg in the control group). 
No difference was observed for arterial carbon di- 
oxide tension among the different groups (p = 0.6). 
Wet/dry weight ratio (Fig. 6). Only group 
NO+PTX exhibited a significantly decreased wet/ 
dry ratio, a measure of lung permeability to fluid, as 
compared with all other groups (p = 0.04). 
Graft PMN sequestration (Fig. 7). PMN seques- 
tration into reperfused tissues is time-dependent, is 
Inasmuch as all recipients in groups control and 
PTX died within 40 minutes of reperfusion, samples 
for MPO determination were frozen after less reper- 
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Fig. 6. Grafted lung wet/dry weight ratio (W/D). Data are 
shown as the mean _+ standard error of the mean. *p < 
0.05 versus control group; -~p < 0.05 versus pentoxifylline 
(PTX) group; :~p < 0.05 versus NO group. 
fusion time than those in groups NO and NO+PTX. 
Therefore groups control and PTX (Fig. 7, right 
panel) and groups NO and NO+PTX (Fig. 7, left 
panel) were compared separately. Groups control 
and PTX exhibited no differences in MPO activity. 
However, graft PMN sequestration was significantly 
inhibited after NO+PTX as compared with NO 
alone (p = 0.01). 
Discussion 
This study demonstrates that inhaled NO, given 
during cadaver ventilation and repeffusion, facili- 
tates distribution of the flush solution, prevents 
ischemia-reperfusion-induced pulmonary vasocon- 
striction, and results in improved survival after 
transplantation f lungs from non-heart-beating do- 
nors. Addition of PTX to NO during reperfusion 
results in decreased PMN sequestration i  the graft, 
decreased edema (wet/dry ratio), improved pulmo- 
nary hemodynamics and oxygenation, and further 
enhanced survival. In this model, PTX alone was not 
protective, but a synergistic effect of NO and PTX 
was observed. 
The present protocol was chosen in an attempt to 
reproduce the conditions to be encountered in 
clinical lung transplantation from non-heart-beating 
donors. These conditions associate an in situ warm 
ischemic period followed by cold ischemia and 
transplantation. We used cadaver ventilation be- 
cause it has been shown to reduce ischemic damage 
in experimental non-heart-beating donor lung trans- 
plantation. 3 We did not heparinize the animals 
before putting them to death. This is in agreement 
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with a recent study 2 showing that experimental 
non-heart-beating donor lung transplantation can 
be done without heparinization. Ligating the con- 
tralateral pulmonary artery keeps the animals to a 
rigorous functional standard, in which the entire 
cardiac output is directed toward the allograft and 
survival entirely depends on graft viability. 16 Be- 
cause of the ischemia-reperfusion-induced pulmo- 
nary hypertension, ligation of the right pulmonary 
artery places an acute strain on the right side of the 
heart, and death occurred less from hypoxia than 
from right ventricular failure. 
Beneficial effects on non-heart-beating donor 
grafts have previously been reported with the use of 
free radical scavengers 2 and urokinase. 19NO, by 
maintaining endothelial homeostasis, vasodilating 
the pulmonary arterial bed, and inhibiting PMN and 
platelet adherence, exerts a protective effect in 
ischemia-reperfusion injury] Prevention of pulmo- 
nary ischemia-reperfusion injury after heart-beating 
donor lung transplantation has recently been 
achieved by stimulation of the distal NO pathway, 16 
NO donors in the flush solution, 2° or NO inhala- 
tion. 1° Our choice to use NO inhalation as a means 
to prevent ischemia-reperfusion njury after non- 
heart-beating donor transplantation is based on the 
fact that gaseous NO can be delivered irectly to the 
pulmona~ endothelium by ventilation, even after 
cessation of circulation. Furthermore, a study by our 
group a° showed that inhaled NO, applied at reper- 
fusion, attenuates i chemia-reperfusion injury after 
porcine lung transplantation. We 21 also found that it 
prevents endothelial dysfunction, pulmonary hyper- 
tension, and PMN sequestration after warm lung 
ischemia nd reperfusion i an isolated porcine lung 
preparation. Nevertheless, the use of inhaled NO in 
ischemia-reperfusion njury remains controversial, 
because xogenous NO can combine with superox- 
ide anions to generate toxic intermediates such as 
peroxynitrite. 22 Eppinger and associates 23 reported 
this phenomenon i pulmonary ischemia-reperfu- 
sion injury. However, very high doses of inhaled 
NO (80 ppm) were used in this later study. In 
contrast to the present experiment, Naka and asso- 
ciates 16 did not find an improved survival with 
inhaled NO after lung transplantation in the heart- 
beating donor rat model. Although experimental 
conditions (warm vs cold ischemia, flush solution, 
higher NO concentration) differed, we used inhaled 
NO throughout the period of in situ warm ischemia, 
because a recent study shows that ischemia-reperfu- 
sion injury in lungs from non-heart-beating donors is 
further educed when NO is given during both warm 
ischemia nd reperfusion, as compared with admin- 
istration of NO during reperfusion only. 24 Possible 
mechanisms include inhibition of xanthine oxi- 
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daseY which accumulates during ischemia nd re- 
acts with oxygen and hypoxanthine to produce a 
burst of superoxide and hydrogen peroxide at reper- 
fusion. The beneficial effect seen in our study could 
also be explained by the vasodilator effect of NO 
during administration f the flush solution, resulting 
in shorter flush times seen in both groups in which 
inhaled NO was used and suggesting a more even 
distribution of the preservation solution during cold 
ischemia. 
Several groups recently reported that PTX was 
beneficial after ischemia-reperfusion injury in an ex 
vivo lung model and improved survival in large- 
animal lung transplantation. < 11-13 This effect was 
associated with reduced PMN sequestration. As 
opposed to these findings, PTX alone did not im- 
proved PMN lung sequestration, pulmonary vaso- 
constriction, and survival. PMN sequestration was 
relatively low in groups that received PTX but not 
significantly different from that in the control group. 
This is likely due to the lower pulmonary arterial 
blood flow in the transplanted lung and shorter 
survival of these groups, resulting in less reperfusion 
time and thus less PMN adhesion.IS PTX has been 
reported to have a vasodilatory effect, but this effect 
was seen at relatively higher concentrations. 26 Fi- 
nally, PTX was given only during reperfusion i the 
present study and was not added to the flush solu- 
tion. A recent study indicated in a canine lung 
transplantation model that PTX used during reper- 
fusion did not improve survival as compared with 
PTX administration in the flush solution. 11 
Although PTX alone did not reduce PMN seques- 
tration, its addition to inhaled NO resulted in a 
further eduction in PMN sequestration. Analogous 
to the effect on PMN sequestration, a synergistic 
effect on the pulmonary vasculature was also ob- 
served, resulting in improved oxygenation and right 
ventricular function, decreased wet/dry ratio, and 
comparatively better survival in animals treated with 
NO and PTX. Possible mechanisms include inhibi- 
tion of expression of adhesion molecules located on 
PMNs, either directly 27 or through adecrease in the 
production of various cytokines, such as tumor 
necrosis factor-c~, 2s radical oxygen species scaveng- 
ing, 29 improvement of microcirculation, 3° and pre- 
vention of ischemia-reperfusion-induced endothe- 
lial dysfunction. 5 Recent investigative work has 
shown that PTX-induced protection can involve 
different pathways than NO-induced protection. 5 
For example, a recent study concluded that PTX 
reversed tumor necrosis factor-induced ndothelial 
dysfunction, whereas L-arginine did not. xs The noted 
synergistic effect could also be a reflection of the 
improved perfusion induced by inhaled NO, result- 
ing in facilitated istribution of PTX to the micro- 
circulation. 29Further experiments should confirm 
the beneficial effects of combined NO and PTX 
treatment in a large animal, non-heart-beating do-
nor model. 
Our findings are clinically relevant. Inhaled NO 
and PTX have both been used in clinical practice for 
a number of years, and widespread organ shortage 
would be lessened if lungs from non-heart-beating 
donors could be used. In conclusion, we found that 
PTX administration during reperfusion alone was 
not beneficial in this model, whereas inhaled NO 
was beneficial after non-heart-beating donor lung 
transplantation in terms of survival and prevention 
of ischemia-reperfusion-induced pulmonary vaso- 
constriction. Treatment with PTX and NO resulted 
in a synergistically enhanced protection from isch- 
emia-reperfusion injury and further improved sur- 
vival. This is likely the result of a dual vasculature 
and PMN sequestration. 
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